143
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
TO THE QUESTION OF CHOOSING THE RESEARCH OBJECT ON THE TOPIC
OF NOOTROPIC DRUGS
Ismailova M.K.
1
Yunusova Kh.M.
2
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
e-mail: ismailova.muhayyo.1987@gmail.com
https://doi.org/10.5281/zenodo.17326318
Relevance:
Nootropic drugs occupy a key place in modern neurological and psychiatric
practice, as they help improve cognitive functions, memory recovery, concentration, and
neuroplasticity. Their use is particularly relevant in the rehabilitation of patients after serous
meningitis, traumatic brain injuries, strokes, and other neuroinfections accompanied by cognitive
impairments. According to DRUG-audit data for 2022–2024, the Republic of Uzbekistan has
witnessed not only a steady increase in sales of nootropic drugs but also an expansion of their
therapeutic applications. The share of nootropics in the psychoanaleptic drug segment consistently
exceeds 85% of the total pharmaceutical market in this category. The greatest interest is shown in
drugs with the International Nonproprietary Names (INN) - Piracetam, Citicoline, Hopantenic acid,
and Meclofenoxate - which demonstrate high prescription rates, proven efficacy, and favorable
clinical outcomes. Additionally, pharmacoeconomic factors such as the affordability of drugs for
different population groups and their inclusion in therapy standards are taken into account.
Research Objective:
To determine the optimal object for subsequent pharmacological and
clinical studies among nootropic drugs, taking into account DRUG-audit data, INNs, clinical efficacy
indicators, safety profiles, and economic feasibility.
Materials and Methods:
The study included a comprehensive analysis of DRUG-audit
statistical data covering sales volumes, consumption dynamics, and price segments of nootropic drugs
for 2022–2024. Comparative analysis methods were additionally used to evaluate pharmacological
properties, safety profiles, and frequency of clinical use of drugs with different INNs. To enhance
objectivity, information from international databases and recommendations from clinical protocols
on the use of nootropics in neurorehabilitation were also utilized.
Results:
According to DRUG-audit data, drugs with the INNs Piracetam and Citicoline
consistently hold leading positions in terms of sales volumes and prescription frequency, accounting
for over 40% of the entire nootropic drug market. Drugs with the INNs Hopantenic acid and
Meclofenoxate, although occupying a smaller market share, demonstrate a steady positive trend due
to their active use in the rehabilitation of patients after neurological diseases and in pediatric practice.
Conclusions:
Based on a comprehensive analysis, drugs with the INNs Citicoline and
Hopantenic acid can be recommended for further pharmacological and clinical studies. They possess
proven clinical efficacy, pronounced neuroprotective effects, acceptable safety profiles, and high
usage frequency in real-world medical practice. The use of DRUG-audit data in combination with
INN analysis and pharmacoeconomic factors makes it possible to justify the choice of the research
object not only from a clinical but also from an economic and social perspective. This is an important
aspect for developing a rational pharmacotherapy strategy for cognitive disorders and rehabilitation
of patients with neurological pathology.
